• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by TScan Therapeutics Inc.

    8/23/24 5:50:56 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001741285
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Tscan Therapeutics, Inc.
    SEC File Number
    001-40603
    Address of Issuer
    830 WINTER STREET
    WALTHAM
    MASSACHUSETTS
    02451
    Phone
    857-399-9500
    Name of Person for Whose Account the Securities are To Be Sold
    ZDRAVESKI ZORAN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Services
    200 W Civic Center Dr - 4th Floor
    Sandy � UT � 84070
    164686905773.004870000008/23/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON08/23/2024STOCK OPTION EXERCISEISSUERCheckbox not checked15718608/23/2024COMPENSATION
    COMMON12/31/2022ESPPISSUERCheckbox not checked750012/31/2022COMPENSATION

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/23/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Zoran Zdraveski

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TCRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TCRX

    DatePrice TargetRatingAnalyst
    11/14/2025Overweight → Equal-Weight
    Morgan Stanley
    5/16/2024$12.00Buy
    BTIG Research
    5/13/2024$11.00Buy
    Needham
    6/22/2023$8.00Outperform
    Wedbush
    12/16/2021$21.00Buy
    HC Wainwright & Co.
    8/13/2021Outperform
    Cowen & Co.
    8/10/2021$22.00Overweight
    Barclays
    8/10/2021$22.00Overweight
    Morgan Stanley
    More analyst ratings

    $TCRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

    Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs from validated mechanisms[1]. Antibody-drug conjugate pipelines expanding past 200 clinical candidates demonstrate how platform technologies enable rapid target-swapping while preserving core therapeutic advantages, creating sustainable competitive moats that command premium valuations[2]. This structural shift toward modularity positions companies with proprietary engines to capture multiple therapeutic opportunit

    12/19/25 7:55:00 AM ET
    $ADCT
    $CRNX
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

    WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition and the future market opportunity for its heme program. The virtual event will take place on Monday, December 8, at 8:00 a.m. ET. The event will provide an in-depth review of the poster presented at the ASH A

    12/3/25 4:05:00 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Amello Jason

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    1/22/26 5:52:24 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Macbeath Gavin

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    1/22/26 5:48:44 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Dworak Leiden

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    1/22/26 5:30:20 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCRX
    SEC Filings

    View All

    TScan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

    1/12/26 7:30:19 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by TScan Therapeutics Inc.

    8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

    11/26/25 4:15:12 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by TScan Therapeutics Inc.

    10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)

    11/12/25 7:30:45 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TScan Therapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded TScan Therapeutics from Overweight to Equal-Weight

    11/14/25 10:24:29 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BTIG Research initiated coverage on TScan Therapeutics with a new price target

    BTIG Research initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $12.00

    5/16/24 7:35:53 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Needham initiated coverage on TScan Therapeutics with a new price target

    Needham initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $11.00

    5/13/24 8:33:06 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lynx1 Capital Management Lp bought $73,552 worth of shares (81,732 units at $0.90) and bought $71,974 worth of shares (80,069 units at $0.90) (SEC Form 4)

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    12/23/25 6:17:28 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $1,666,553 worth of shares (1,388,794 units at $1.20) and bought $1,440,000 worth of shares (1,200,000 units at $1.20) (SEC Form 4)

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    5/21/25 4:49:27 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $95,629 worth of shares (31,800 units at $3.01) and bought $290,140 worth of shares (100,000 units at $2.90) (SEC Form 4)

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    12/16/24 4:26:18 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCRX
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

    WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries. "We are delighted to welcome Stephen to TScan at this stage of growth for the Company," said Gavin MacBeath, Ph.D., Chief Executive Officer.

    3/27/25 7:00:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T

    8/12/24 7:00:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCRX
    Financials

    Live finance-specific insights

    View All

    TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

    Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to focus clinical development on heme program and initiate pre-clinical development of in vivo-engineered TCR-T for solid tumors Strategic prioritization extends cash runway into H2 2027 Conference call and webcast scheduled for Monday, November 3, 8:00 a.m. Eastern Time WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology comp

    11/3/25 6:30:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

    All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) --  TScan Th

    2/26/24 7:00:00 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

    Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and is eligible t

    5/9/23 9:00:00 AM ET
    $AMGN
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

    SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

    11/14/24 4:40:11 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

    SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

    11/14/24 4:05:31 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

    SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

    11/14/24 3:05:59 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care